文献速递心外重症与机械循环支持

Impella 5.5 泵的临床管理

Clinical management of the Impella 5.5 pump.
PubMed 文献 · J Heart Lung Transplant · 2025-06-24

本文系统综述了 Impella 5.5 微轴流泵在心源性休克患者中的临床管理,涵盖患者选择、手术植入、围术期管理、抗凝策略、术后监测及并发症处理,并提出三期康复框架和多学科协作的重要性,旨在标准化管理、减少并发症并改善预后。

要点

  • Impella 5.5 提供高达 5.5 L/min 前向血流,适用于桥接恢复或心脏替代治疗。
  • 经腋动脉植入最常见,需关注出血、溶血、右心衰、卒中等并发症。
  • 推荐三期康复框架:血流动力学稳定、启动指南导向药物治疗、结构化撤机。

核心结论

  • 通过整合现有证据和机构经验,标准化 Impella 5.5 管理可减少并发症并改善危重心衰或心源性休克患者预后。

研究设计与样本

  • 本文为综合性结构化临床管理指南,基于现有证据和机构经验总结。

主要发现

  • Impella 5.5 提供高达 5.5 L/min 的血流,实现全左心室支持,具有有益的血流动力学和代谢效应。
  • 其独特优势包括高流量、前向循环支持及潜在长期使用,适合桥接至恢复或心脏替代治疗。

关键数值与推荐

  • 患者选择、手术植入(最常见经腋动脉)、围术期管理、抗凝策略和术后监测的最佳实践。
  • 并发症管理重点包括出血、溶血、右心室功能障碍、卒中、主动脉瓣损伤和血管并发症。
  • SmartAssist 和 Impella Connect 可用于实时设备监测和远程管理。
  • 三期康复框架:血流动力学稳定、启动指南导向药物治疗(GDMT)、结构化撤机方案。
  • 过渡至心脏移植或持久左心室辅助装置(LVAD)的考虑及撤除技术。

临床怎么用

  • 临床中应按照指南进行患者选择、植入和围术期管理,并加强并发症监测与处理。
  • 利用 SmartAssist 和 Impella Connect 进行实时监测和远程管理。
  • 遵循三期康复框架,逐步过渡到指南导向药物治疗和撤机。
  • 强调多学科协作,包括机械循环支持(MCS)协调员,以优化患者结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Impella 5.5 (Abiomed, USA) is a catheter-based micro-axial flow pump that has emerged as a vital tool in managing patients with cardiogenic shock (CS). Delivering up to 5.5 L/min of flow, it enables full left ventricular (LV) support with beneficial hemodynamic and metabolic effects. Its unique advantages include high-flow, antegrade circulatory support with the potential for prolonged usage, making it suitable for bridging to recovery or heart replacement therapies. This manuscript provides a comprehensive, structured guide for the clinical management of patients supported with the Impella 5.5. It outlines best practices for patient selection, surgical implantation techniques-most commonly via the axillary artery-perioperative management, anticoagulation strategies, and postoperative monitoring. Special emphasis is placed on complication management, including bleeding, hemolysis, right ventricular dysfunction, stroke, aortic valve injury, and vascular complications. Technologies like SmartAssist and Impella Connect are highlighted for their utility in real-time device monitoring and remote management. The manuscript also discusses a three-phase framework for recovery: hemodynamic stabilization, initiation of guideline-directed medical therapy (GDMT), and structured weaning protocols. Considerations for transitioning patients to heart transplantation or durable LVADs, as well as explant techniques, are detailed. The importance of multidisciplinary coordination-including a mechanical circulatory support (MCS) coordinator-is emphasized to ensure optimal patient outcomes. By synthesizing available evidence and institutional experience, this guide aims to standardize Impella 5.5 management, reduce complications, and improve outcomes in critically ill patients with advanced heart failure or CS.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Bernhardt AM, Blumer V, Vandenbriele C, et al. Clinical management of the Impella 5.5 pump. J Heart Lung Transplant. 2025. PMID: 40571169. doi:10.1016/j.healun.2025.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。